Confidently conduct research in
sub-saharan africa

Take advantage of our long-standing relationships, local team and broad expertise to expand your research across sub-Saharan Africa.
Geographic footprint
localized expertise
therapeutic areas
partnerships
Sites in Africa

we have a broad geographic footprint

Leverage our unique, localized view using our established resources and research experience in 389 studies across the 31 countries highlighted in blue in the map below.

Our far-reaching, in-country technical, regulatory and cultural knowledge has been developed over our long history of working in sub-Saharan Africa.

We’ve supported first-in-human to phase 4 clinical trials as well as epidemiological, observational and bioequivalence studies for pediatric and adult populations.

Data current as of July 1, 2023. The boundaries and names on this map do not imply official endorsement or acceptance by FHI Clinical.

FHI Clinical Presence

FHI Clinical & FHI 360

FHI 360 Locations

We are localized

100
Local team members

Our localized team has the experience and skills to support your portfolio strategy, determine feasibility, rapidly develop sites and provide end-to-end study support.

Our experience helps guide decisions about the best-fit countries and populations for your target indication and study type while being sensitive to cultural nuances and the specific needs of the local communities.

We have an FHI Clinical SA office in Centurion, South Africa and FHI Clinical offices in Nairobi, Kenya, and Monrovia, Liberia.

Meet some of our team members in sub-Saharan Africa.

Victor Taryor, Site Manager at the John F. Kennedy Medical Center, Liberia
Learn more
Dr. Kumblytee Johnson, Site Physician, Clinical Investigator and Principal Investigator, Liberia
Learn more
Stephanie Nono, Clinical Research Associate, based in Côte d’Ivoire
Learn more
Daniel Joffe, Senior Clinical Project Manager, based in South Africa
Learn more

WE SUPPORT MANY THERAPEUTIC AREAS

Leverage our previous and ongoing experience conducting studies in sub-Saharan Africa across nearly 20 therapeutic areas in both pediatric and adult populations.

SPECIFIC INFECTIOUS DISEASE EXPERTISE IN SUB-SAHARAN AFRICA

Given the high burden of infectious diseases, neglected tropical diseases and emerging and reemerging diseases in vulnerable populations in this geographic area, we are committed to helping eradicate these diseases through a combination of vaccines, preventive therapies, spatial repellents and treatments. Our experience spans 236 studies across 26 indications.

we are a trusted partner

We are dedicated to developing and maintaining relationships with governments, regulatory agencies, other contract research organizations, sponsors, academic institutions, research sites and local communities. Importantly, we commit the needed resources to those relationships and become a trusted partner.

Participation in research networks

As a trusted network partner, we have unique insights that contribute to protocol development, regulatory oversight, community engagement, liaising with experienced investigators and sites and, when needed, building sustainable research capacity that aligns with the local health and research priorities.

Partnership of Clinical Research in Guinea (PREGUI) and Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) ​
Partnership of Clinical Research in Guinea (PREGUI) and Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) ​

We build sustainable local capacity.

We believe that building and sustaining research capacity, particularly in resource-limited, research-naïve areas, addresses public health issues around the globe. This includes working with regional institutions to establish networks of research-ready sites that focus on local health and research priorities.
Learn about our capacity building services

Sites in Africa

Our database includes 432 research-ready sites across 30 countries, with experience spanning all clinical trial phases, infectious and non-communicable diseases as well as pediatric and adult populations.

Are you a site interested in being considered for future studies with FHI Clinical? Complete the form, and we will contact you to arrange a formal introduction with the FHI Clinical team for further evaluation of your site.

I'm interested in partnering on future studies

Data current as of July 1, 2023. The boundaries and names on this map do not imply official endorsement or acceptance by FHI Clinical.

Learn more about our specific experience through our case studies:

Case Study
CaseStudy_Thumb_CHIKV_1200x630

Phase II Trial of a Chikungunya Vaccine in the Caribbean

The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Read more
Case Study
Feature_sitemanagement_1200x630

Site Monitoring & Management in a Clinical Trial of a Spatial Repellent for Vector-Borne Disease Control

The FHI Clinical project team supported site monitoring, site management and project management to assist the University of Notre Dame investigators achieve a level of rigor not typically required for a non-medical product in their double-blinded, randomized-cluster, placebo-controlled clinical trial of a spatial repellent against mosquitoes for malaria prevention.
Read more
Case Study
Map_Thumb_1200x630_Africa-Mozambique-Maputo

Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
Read more
Case Study
Map_Thumb_1200x630_Africa-EquatorialGuinea

Providing Site Monitoring and Management Expertise in Malaria Vaccine Trials in Equatorial Guinea

Data monitoring strategies implemented by our bilingual CRA helped eliminate the backlog to ensure timely database lock in a phase 2 trial for Sanaria's innovative PfSPZ Vaccine for malaria in Equatorial Guinea, an area with limited prior research experience.
Read more
Case Study
CaseStudy_Thumb_1200x630_Zika

Phase II/IIb Trial of a Zika Vaccine Spanning Nine Countries

In a study conducted at 17 sites spanning nine countries in a Zika endemic region of the Americas and Caribbean, timely staffing of contract research associates (CRAs) was enabled by the project team’s network of bilingual resources and knowledge of local hiring practices.
Read more
Case Study
CaseStudy_Thumb_1200x630_TrainingLiberia

Clinical Research Training to Support Capacity Building in Liberia

To equip Liberia with the ability to respond to ongoing health issues and potential outbreaks, a US government contract provided funding to train local leaders in Liberia’s clinical research infrastructure network. The training aimed to build a solid foundation to conduct international quality clinical research.
Read more
Case Study
CaseStudy_Thumb_1200x630_TB

Building Capacity for Tuberculosis Research in China: The China TB Clinical Trials Consortium (CTCTC)

To help address the high global TB incidence and related death rate, the China TB Clinical Trials Consortium (CTCTC) was established by government and industry partners to help build clinical research capacity in China, which has a particularly high tuberculosis incidence.
Read more
Case Study
CaseStudy_Thumb_1200x630_Ebola

Rapid Study Start-Up for the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)

Within a challenging, resource-limited setting, the project team succeeded in reaching FP/FV six weeks after arrival in Sierra Leone and 99.998% accuracy of the planned-to-execute budget.
Read more
Case Study
CaseStudy_Thumb_1200x630_Oncology

Rescue of an Ongoing Global, Multi-Site Oncology Trial

In a Phase 3 study with a lengthy intervention for colorectal cancer, the project team reached a 70% retention rate, with steadily increasing enrollment rates, by implementing strategies to address poor patient enrollment and retention.
Read more

View additional resources describing our experience in sub-Saharan Africa: